GBS (GBS) Competitors

GBS (NYSE:GBS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Do insiders and institutionals hold more shares of GBS or INFU?

2.8% of GBS shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 0.3% of GBS shares are owned by company insiders. Comparatively, 10.2% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has better earnings & valuation, GBS or INFU?

InfuSystem has higher revenue and earnings than GBS. GBS is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GBS	N/A	N/A	-$8.31M	-$0.56	-3.39
InfuSystem	$137.58M	0.92	$870K	$0.14	42.93

Does the media refer more to GBS or INFU?

In the previous week, InfuSystem had 8 more articles in the media than GBS. MarketBeat recorded 9 mentions for InfuSystem and 1 mentions for GBS. InfuSystem's average media sentiment score of 0.80 beat GBS's score of 0.25 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GBS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, GBS or INFU?

GBS has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Do analysts rate GBS or INFU?

InfuSystem has a consensus target price of $12.50, suggesting a potential upside of 107.99%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than GBS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GBS	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	4.00

Is GBS or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to GBS's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GBS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GBS	N/A	-85.64%	-54.42%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats GBS on 15 of the 15 factors compared between the two stocks.